Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Brilacidin has passed safety benchmarks in multiple clinical trials and, is currently being tested in two US RBL’s for covid.

Brilacidin for ABSSSI is ph3 ready. Ph2 was dosed via IV in hundreds of patients.

Brilacidin for OM is ph3 ready. Ph2 was dosed via swish and spit.

Brilacidin for UP ph 2 POC trial was dosed with water enema. Results good enough that Alfasigma licensed Brilacidin for UP dosing with foam, enema, or gel.

Brilacidin for UC ph 1 was dosed with Oralogic tablet.

http://www.ipharminc.com/press-release/2020/5/26/innovation-pharmaceuticals-receives-data-from-public-health-research-institute-showing-brilacidin-inhibits-sars-cov-2-covid-19-in-a-human-cell-line

· Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2
· Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells